Adult Malignant Glioma Therapeutics Market report covers top players as Merck & Co., Inc., Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, Pfizer Inc., AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Novocure

Adult Malignant Glioma Therapeutics Market Recent Trends, Competitive Landscape, and Growth by Forecast to 2026

The Global Adult Malignant Glioma Therapeutics Market is likely to grow in the coming years due to advancements made in targeted therapy to treat malignant glioma. According to a report published by Fortune Business Insights, titled “Adult Malignant Glioma Therapeutics: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 1,459.1 Mn.

Fortune Business Insights states that the market is likely to reach US$ 2,964.5 Mn at a CAGR of 9.3% in the forecast period.

Some of the leading companies that are operating in the Global Adult Malignant Therapeutics Market are;

  • Merck
  • Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals
  • Pfizer
  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Sun Pharmaceutical Sdn Bhd
  • Teva Pharmaceuticals. and Novocure

Get Sample PDF Brochure at

According to the World Health Organization (WHO), almost 2,45,000 brain tumor cases are registered every year. Despite advancements in treatment options and awareness regarding prevention of tumor at an early stage, the incidence of brain tumor has been on the rise. With increasing glioma cases and a low survival rate among people diagnosed with glioma, there are several market players focusing solely on the research and development of novel therapeutics to treat adult malignant glioma. The aforementioned factors are driving the global adult malignant glioma therapeutics market.

New Imaging Technique May Help Remove Malignant Tumor Altogether

Researchers have come up with a new imaging technique that may help in eliminating the malignant tumor from the human body, altogether. This imaging method may help surgeons locate the tumor with ease. Researchers have claimed that this technique involves the use of a synthetic version of a molecular compound found in the venom of a scorpion. The method also involves the use of an infra-red (IR) camera along with an imaging reagent tozuleristide (BLZ-100). The primary aim of this method was to determine the boundaries between a healthy tissue and tumor. This helps in retaining the healthy tissue after the surgery and thus increases the efficiency of the overall process. Such discoveries are likely to favour growth of the global adult malignant glioma therapeutics market in the forthcoming years.

Browse Complete Report Details at

Blue Earth Announces FDA Clearance for Glioma Drug

In December 2018, Blue Earth announced that it has received FDA clearance for a new drug “Axumin”, which has application in positron emission tomography (PET) imaging for removing tumors. The company announced that Fluciclovin (or Axumin) enables PET imaging that may help detect the precise location of the tumor within the body. Along with precise location, the size and severity of tumor can also be traced. This will massively help in treating the malignant glioma disorder and reduce the overall fatality rate among people diagnosed with this disorder. Thus, the FDA approval will help the company take huge strides towards their aim of developing an efficient malignant glioma treatment method. Blue Earth’s success may have impact on the global adult malignant glioma therapeutics market and will lead to growth of the market in the coming years.

More Trending Topics from Fortune Business Insights:

Electrosurgical Devices Market 2019 Global Industry Share, Size, Future Demand, Global Research, Top Leading Players, Emerging Trends, Region by Forecast to 2026

Facial Injectables Market 2019 Global Size, Growth Insight, Share, Trends, Industry Key Players, Regional Forecast To 2026

Acute Myeloid Leukemia Treatment Market 2019 Company Profiles, Global Trends, Industry Growth, Landscape and Regional Forecast till 2026

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *